Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Subscribe To Our Newsletter & Stay Updated